Advertisement

Topics

ACIP Backs HEPLISAV-B, GMED Hits New High, GWPH's Focal Seizures Trial Fails

00:55 EST 22 Feb 2018 | RTTNews

Today's Daily Dose brings you news about Mesoblast's steroid refractory acute Graft versus Host Disease trial results; CHMP's positive trend vote for Rucaparib in ovarian cancer and HEPLISAV-B vaccine getting favorable recommendation from the CDC's Advisory Committee on Immunization Practices.

Original Article: ACIP Backs HEPLISAV-B, GMED Hits New High, GWPH's Focal Seizures Trial Fails

NEXT ARTICLE

More From BioPortfolio on "ACIP Backs HEPLISAV-B, GMED Hits New High, GWPH's Focal Seizures Trial Fails"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...